Company: MDCXW
Filing Date: 2025-06-23
Form Type: CORRESP
Source: 0001062993-25-012069
Chunk: 0

Company: Medicus Pharma Ltd.
Filing Date: 2025-06-23
Form: CORRESP
Chunk 0
---
<div align='center'>Paul, Weiss, Rifkind, Wharton & Garrison LLP
1285 Avenue of the Americas
New York, New York 10019-6064</div>

June 23, 2025

Division of Corporation Finance

Office of Life Sciences

Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549

Re:Medicus Pharma Ltd.
Preliminary Proxy Statement on Schedule 14A
Filed June 13, 2025
File No. 001-42408

Ladies and Gentlemen:

On behalf of Medicus Pharma Ltd. (the "Company"), we acknowledge receipt of the letter from the Staff of the Division of Corporation Finance (the "Staff") of the Securities and Exchange Commission (the "Commission"), dated June 20, 2025 (the "Comment Letter"), with respect to the Company's Preliminary Proxy Statement on Schedule 14A, File No. 001-42408, filed with the Commission on June 13, 2025 (the "Proxy Statement").

Concurrently with the submission of this letter, the Company is filing Amendment No. 1 to the Proxy Statement ("Amendment No. 1"), which reflects changes made in response to the Comment Letter, and certain other updates. For your convenience, each response is prefaced by the exact text of the Staff's corresponding comment in bold, italicized text.

1.We note that Proposal 5 is seeking shareholder approval of a special resolution that would authorize the Board of Directors to approve a consolidation or share split of the Company's Common Shares "at a consolidation or share split ratio...to be determined by the Board in its sole discretion". Please revise here and throughout your preliminary proxy statement to disclose a possible range of the potential consolidation ratio, or advise.

Response: The Company acknowledges the Staff's comment. The Company advises the Staff that the Company is no longer seeking shareholder approval of a special resolution that would authorize the Board of Directors to approve a consolidation or share split of the Company's Common Shares. The Company has revised the Proxy Statement throughout to reflect the fact that Proposal 5 in the Proxy Statement has been removed from Amendment No. 1 and that Proposal 6 in the Proxy Statement has been renumbered as Proposal 5 in Amendment No. 1.

June 23 2025
Page 2

2.Please revise your disclosure to provide further details about the reasons for the potential consolidation or share split including, but not limited to,